Sexual Functioning After Primary Treatment of Ovarian Cancer
The purpose of this study is to help us learn more about sexual problems after treatment for ovarian cancer. At this time, we do not know how many women have sexual problems after they are treated for ovarian cancer.
How common are sexual problems after treatment for ovarian cancer?
- What factors make women more likely to have sexual problems after treatment for ovarian cancer?
- What happens to sexual functioning over the first 12 months after treatment? ie.
Does it get better or worse?
• Does referral to a specialized sexual health clinic help?
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Sexual Functioning After Primary Treatment of Ovarian Cancer|
- To estimate the prevalence of sexual dysfunction, as measured by Female Sexual Functioning Index (FSFI) among women who have completed first-line treatment for ovarian cancer within the last 6 months and currently have no evidence of disease. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
- To study the natural history of sexual functioning in women after primary treatment of ovarian cancer by using the FSFI at approximately 3, 6 and 12 months. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]
|Study Start Date:||November 2004|
|Study Completion Date:||November 2015|
|Primary Completion Date:||November 2015 (Final data collection date for primary outcome measure)|
FSFI score <= 26
will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
FSFI score >26
Those women who have a FSFI score > 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00596544
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Elizabeth Jewell, MD||Memorial Sloan Kettering Cancer Center|